Edwards Inspiris Resilia«Prosthesis For Aortic Valve Replacement In Young Adults: Short-term And Mid-term Clinical Outcome And Haemodynamic Performances
Alessandra Francica, FIippo Tonelli, Cecilia Rossetti, Ilaria Tropea, Luciana Benvegn¨, Giovanni Battista Luciani, Giuseppe Faggian, Francesco Onorati
University of Verona Medical School, Verona, Italy.
OBJECTIVE: Edwards INSPIRIS RESILIA« is a new generation of bio-prosthesis which aimed to reduce the structural valve degeneration (SVD) in young patients requiring aortic valve replacement (AVR). Scanty data exist about clinical outcome and haemodynamic performances in clinical practice. The aim of the study is to assessed short-term and mid-term major clinical and echocardiographic outcome in young patients receiving INSPIRIS RESILIA.
METHODS: All adult patients receiving an INSPIRIS RESILIA valve for AVR between 2017 and 2021 were enrolled. Kaplan-Meier curves were used to assess overall and cardiovascular survival, freedom from reoperation, SVD, endocarditis and from re-hospitalization. Short-term and mid-term echocardiographic data were assessed. Time-dependent effect of valve performance was assessed with 2-way ANOVA.
RESULTS: 161 patients received INSPIRIS RESILIA valve. Mean age was 56.8▒10.0 years; 66% had ?60 years at surgery. Overall-survival was 99.4% and 93.8% at 30-days and 3 years respectively, while freedom from cardiovascular death and from SVD was 100%. Only one patient underwent reoperation for endocarditis, while two patients required pace-maker implantation.Considering patients requiring AVR for aortic stenosis, a reduced trans-aortic mean gradient was noted after surgery and a stable haemodynamic profile was maintained during follow-up (Gmean 42.1▒14.2 pre-op vs 11.7▒4.3 at 30-days, 12.9▒4.4 at 3 years, p<.01). Patients requiring AVR for valve regurgitation further demonstrated stable left ventricular reverse remodelling during follow-up (LVEDV preoperative: 238.5▒131.04 ml vs 3 years: 123.8▒32.5 ml, p<.01).
CONCLUSIONS: INSPIRIS RESILIA valve is safe and effective in young patients. Excellent haemodynamic performances are obtained at short-term and mid-term follow-up.
Back to 2022 Abstracts